In the 2021 WHO classification of CNS tumors, CDKN2A/B homozygous deletion became one of the bases of glioma classification, which emphasized the importance of CDKN2A in the development of glioma (Louis et al., 2021; Komori, 2022). This evidence concerns the gene CDKN2A and glioma.